Adverse events273

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 273

Type	Event	Organ system	Group	Affected	At risk	Events
other	Amylase increased	Investigations	Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label)	0	27	0
other	Amylase increased	Investigations	Part B: Peginterferon Lambda-1a + RBV + TVR	21	411	26
other	Amylase increased	Investigations	Part B: Peginterferon Alfa-2a + RBV + TVR	3	206	5
other	Blood bilirubin increased	Investigations	Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label)	2	27	3
other	Blood bilirubin increased	Investigations	Part B: Peginterferon Lambda-1a + RBV + TVR	19	411	25
other	Blood bilirubin increased	Investigations	Part B: Peginterferon Alfa-2a + RBV + TVR	2	206	2
other	Alanine aminotransferase increased	Investigations	Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label)	2	27	2
other	Alanine aminotransferase increased	Investigations	Part B: Peginterferon Lambda-1a + RBV + TVR	30	411	33
other	Alanine aminotransferase increased	Investigations	Part B: Peginterferon Alfa-2a + RBV + TVR	1	206	2
other	Aspartate aminotransferase increased	Investigations	Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label)	1	27	1
other	Aspartate aminotransferase increased	Investigations	Part B: Peginterferon Lambda-1a + RBV + TVR	30	411	38
other	Aspartate aminotransferase increased	Investigations	Part B: Peginterferon Alfa-2a + RBV + TVR	1	206	2
other	Bilirubin conjugated increased	Investigations	Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label)	2	27	2
other	Bilirubin conjugated increased	Investigations	Part B: Peginterferon Lambda-1a + RBV + TVR	6	411	9
other	Bilirubin conjugated increased	Investigations	Part B: Peginterferon Alfa-2a + RBV + TVR	1	206	1
other	Dyspnoea	Respiratory, thoracic and mediastinal disorders	Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label)	2	27	2
other	Dyspnoea	Respiratory, thoracic and mediastinal disorders	Part B: Peginterferon Lambda-1a + RBV + TVR	31	411	34
other	Dyspnoea	Respiratory, thoracic and mediastinal disorders	Part B: Peginterferon Alfa-2a + RBV + TVR	37	206	41
other	Cough	Respiratory, thoracic and mediastinal disorders	Part A: Peginterferon Lambda-1a + RBV + TVR (Open Label)	3	27	3
other	Cough	Respiratory, thoracic and mediastinal disorders	Part B: Peginterferon Lambda-1a + RBV + TVR	12	411	13

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01598090/events

API reference For AI assistants

Adverse events273

Sources 3

Read this list from software.